News | July 27, 2025
Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The company showcased three core programs developed through this platform
Subscribe To Our Newsletter & Stay Updated
